These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37308686)

  • 1. Predicting TERT promoter mutation status using
    Yamashita K; Hatae R; Kikuchi K; Kuga D; Hata N; Yamamoto H; Obara M; Yoshimoto K; Ishigami K; Togao O
    Neuroradiology; 2023 Aug; 65(8):1205-1213. PubMed ID: 37308686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
    Yamashita K; Hatae R; Hiwatashi A; Togao O; Kikuchi K; Momosaka D; Yamashita Y; Kuga D; Hata N; Yoshimoto K; Suzuki SO; Iwaki T; Iihara K; Honda H
    Diagn Interv Imaging; 2019; 100(7-8):411-419. PubMed ID: 30948344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
    Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
    Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomerase reverse transcriptase promoter mutation and histologic grade in IDH wild-type histological lower-grade gliomas: The value of perfusion-weighted image, diffusion-weighted image, and
    Ikeda S; Sakata A; Fushimi Y; Okuchi S; Arakawa Y; Makino Y; Mineharu Y; Nakajima S; Hinoda T; Yoshida K; Miyamoto S; Nakamoto Y
    Eur J Radiol; 2023 Feb; 159():110658. PubMed ID: 36571926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasively evaluating the grade and IDH mutation status of gliomas by using mono-exponential, bi-exponential diffusion-weighted imaging and three-dimensional pseudo-continuous arterial spin labeling.
    Guo D; Jiang B
    Eur J Radiol; 2023 Mar; 160():110721. PubMed ID: 36738600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced MR imaging and
    Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects.
    Fink JR; Carr RB; Matsusue E; Iyer RS; Rockhill JK; Haynor DR; Maravilla KR
    J Magn Reson Imaging; 2012 Jan; 35(1):56-63. PubMed ID: 22002882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of IDH and TERTp mutation status using
    Ozturk-Isik E; Cengiz S; Ozcan A; Yakicier C; Ersen Danyeli A; Pamir MN; Özduman K; Dincer A
    J Magn Reson Imaging; 2020 Jun; 51(6):1799-1809. PubMed ID: 31664773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas.
    Kong Z; Zhang Y; Liu D; Liu P; Shi Y; Wang Y; Zhao D; Cheng X; Wang Y; Ma W
    Ann Nucl Med; 2021 Apr; 35(4):493-503. PubMed ID: 33532992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS: A Prospective Study.
    Nguyen TB; Melkus G; Taccone M; Moldovan ID; Ghinda D; Gotfrit R; Torres CH; Zakhari N; Chakraborty S; Woulfe J; Jansen G; McInnes MD; Thornhill RE; Cameron I; AlKherayf F
    J Magn Reson Imaging; 2021 Feb; 53(2):416-426. PubMed ID: 32940938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Key Molecular Markers in Adult Diffuse Gliomas Based on a Novel Combination of Diffusion and Perfusion MRI and MR Spectroscopy.
    Su X; Yang X; Sun H; Liu Y; Chen N; Li S; Huang Z; Shao H; Zhang S; Gong Q; Yue Q
    J Magn Reson Imaging; 2024 Feb; 59(2):628-638. PubMed ID: 37246748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
    Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
    Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
    [No Abstract]   [Full Text] [Related]  

  • 15. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.
    Wu CC; Jain R; Radmanesh A; Poisson LM; Guo WY; Zagzag D; Snuderl M; Placantonakis DG; Golfinos J; Chi AS
    AJNR Am J Neuroradiol; 2018 Oct; 39(10):1814-1820. PubMed ID: 30190259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging.
    Liu T; Cheng G; Kang X; Xi Y; Zhu Y; Wang K; Sun C; Ye J; Li P; Yin H
    Neuroradiology; 2018 Jul; 60(7):693-702. PubMed ID: 29777252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
    Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
    J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review.
    Lee D; Riestenberg RA; Haskell-Mendoza A; Bloch O
    J Neurooncol; 2021 Mar; 152(1):89-98. PubMed ID: 33389563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioma grading using multiparametric MRI: head-to-head comparison among dynamic susceptibility contrast, dynamic contrast-enhancement, diffusion-weighted images, and MR spectroscopy.
    Seo M; Choi Y; Soo Lee Y; Ahn KJ; Kim BS; Park JS; Jeon SS
    Eur J Radiol; 2023 Aug; 165():110888. PubMed ID: 37257338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Association between Whole-Brain MR Spectroscopy and IDH Mutation Status in Gliomas.
    Goryawala M; Saraf-Lavi E; Nagornaya N; Heros D; Komotar R; Maudsley AA
    J Neuroimaging; 2020 Jan; 30(1):58-64. PubMed ID: 31868291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.